An experimental vaccine has been shown to protect mice against tuberculosis (TB) and may eventually be suitable for treating human infants living with HIV, a group unable to use the existing TB vaccine, according to a National Institutes of Health (NIH) statement. In a new study, researchers genetically modified a close relative of Mycobacterium tuberculosis, the bacterium that causes TB. The existing Bacille Calmette-Guerin vaccine can cause severe TB infection in HIV-positive infants. The study was funded by the National Institute of Allergy and Infectious Diseases and was published in the journal Nature Medicine.
To read the NIH statement, click here.
Comments
Comments